Nordic Nanovector launches $63m primary block for clinical trials
Tonight, Nordic Nanovector, the Norwegian developer of radio-immunotherapeutics for haematological cancers, is raising Nkr527m ($63m) to finance clinical trials, by placing new shares with institutional investors.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts